Mesenchymal Cell News Volume 13.26 | Jul 6 2021

    By
    Justin.choi
    -
    0
    46







    2021-07-06 | MESCN 13.26


    Mesenchymal Cell News by STEMCELL Technologies
    Vol. 13.26 – 6 July, 2021
    TOP STORY

    Exendin-4 Gene Modification and Microscaffold Encapsulation Promote Self-Persistence and Antidiabetic Activity of MSCs

    Scientists genetically engineered MSCs with Exendin-4, a glucagon-like peptide-1 analog, and demonstrated their boosted cellular functions and antidiabetic efficacy in a type 2 diabetes mellitus mouse model.
    [Science Advances]

    Full Article

    Maximize Post-Thaw Cell Recovery with cGMP-Manufactured Cryopreservation Media. Learn More.
    PUBLICATIONSRanked by the impact factor of the journal
    IN VITRO

    Targeted Cell Therapy for Partial-Thickness Cartilage Defects Using Membrane Modified Mesenchymal Stem Cells by Transglutaminase 2

    By modifying a functional polypeptide on the MSC plasma membrane and exploiting the high expression of transglutaminase 2 in the regions of injured cartilage, researchers achieved targeted recognition and capture of modified MSCs by injured articular chondrocytes
    [Biomaterials]

    Abstract

    Vangl2 Limits Chaperone-Mediated Autophagy to Balance Osteogenic Differentiation in Mesenchymal Stem Cells

    Lysosomes are the recycling center and nutrient signaling hub of the cell. The authors showed that lysosomes also control MSC differentiation by proteomic reprogramming.
    [Developmental Cell]

    Full ArticleGraphical Abstract

    NELL2-cdc42 Signaling Regulates BAF Complexes and Ewing Sarcoma Cell Growth

    Investigators reported that Ewing sarcoma cells were dependent on the autocrine signaling mediated by NELL2, a secreted glycoprotein that has been characterized as an axon guidance molecule.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Systematic Comparison of Promoter, DNA Vector, and Cationic Carrier for Efficient Transfection of Human Mesenchymal Stem Cells from Multiple Donors and Tissue Sources

    The authors investigated two promoters, four DNA vectors, two cationic carriers, and four donors of human MSCs from two tissues for efficient human MSC transfection.
    [Molecular Therapy-Nucleic Acids]

    AbstractFull ArticleGraphical Abstract

    Valproic Acid Stimulates Myogenesis in Pluripotent Stem Cell-Derived Mesodermal Progenitors in a NOTCH-Dependent Manner

    Scientists optimized a protocol to generate chemically defined human induced pluripotent stem cell-derived mesodermal progenitors and they demonstrated that these cells contributed to myotube formation and differentiated into cardiomyocytes.
    [Cell Death & Disease]

    Full Article

    IN VIVO

    Generation of Human Embryonic Stem Cell Models to Exploit the EWSR1-CREB Fusion Promiscuity as a Common Pathway of Transformation in Human Tumors

    Investigators developed in vitro models of oncogenic fusions, in particular, EWSR1-CREB1 and EWSR1-ATF1, in human embryonic stem cells, which were capable of multipotent differentiation, using CRISPR-Cas9 technology and HDR together with conditional fusion gene expression that allowed investigation into the early steps of cellular transformation.
    [Oncogene]

    Abstract

    Sodium Alginate/Collagen/Stromal Cell-Derived Factor-1 Neural Scaffold Loaded with BMSCs Promotes Neurological Function Recovery after Traumatic Brain Injury

    The authors synthesized a sodium alginate (SA)/collagen type I (Col)/stromal cell-derived factor-1 (SDF-1) hydrogel and investigated whether the SA/Col/SDF-1 hydrogel loaded with bone marrow-derived MSCs had therapeutic effects on a traumatic brain injury model.
    [Acta Biomaterialia]

    AbstractGraphical Abstract

    ac4C Acetylation of RUNX2 Catalyzed by NAT10 Promotes Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells and Prevents Ovariectomy-Induced Bone Loss

    Scientists explored the relationships among osteoblast differentiation, N-acetyltransferase 10 (NAT10), and N4-acetylcytidine (ac4C) and found that NAT0 expression and the ac4C level of total RNA were decreased in the bone tissues of OVX mice and osteoporosis patients.
    [Molecular Therapy-Nucleic Acids]

    AbstractFull ArticleGraphical Abstract

    HMGB2 Orchestrates Mitotic Clonal Expansion by Binding to the Promoter of C/EBPβ to Facilitate Adipogenesis

    Researchers provided evidence that high-mobility group box 2 (HMGB2) deficiency in preadipocytes impeded adipogenesis, while overexpression of HMGB2 increased the potential for adipogenic differentiation.
    [Cell Death & Disease]

    Full Article

    Tools and products for your COVID-19 research.
    REVIEWS

    Molecular Mechanisms Underpinning Sarcomas and Implications for Current and Future Therapy

    The authors provide an overview of the molecular mechanisms that underpin sarcomagenesis, the contribution of MSCs to modeling sarcomagenesis in vivo, as well as novel topics such as the role of epithelial-to-mesenchymal-transition/mesenchymal-to-epithelial-transition plasticity, exosomes, and microRNAs in sarcomagenesis.
    [Signal Transduction and Targeted Therapy]

    Full Article

    Advances in Stem Cell Research for the Treatment of Primary Hypogonadism

    Over the past two decades, substantial advances have been made in the identification of Leydig cell sources for use in transplantation surgery, including the artificial induction of Leydig-like cells from different types of stem cells, for example, stem Leydig cells, MSCs, and pluripotent stem cells.
    [Nature Reviews Urology]

    Abstract

    INDUSTRY AND POLICY NEWS

    Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

    Direct Biologics LLC announced that the FDA has approved the application for a Phase I/II trial under an Investigational New Drug (IND) protocol for the use of ExoFloâ„¢ in the treatment of mild-to-moderate COVID-19. ExoFloâ„¢ is an extracellular vesicle product isolated from human bone marrow MSCs.
    [Direct Biologics LLC]

    Press Release

    Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers

    Cynata Therapeutics Limited announced that it has received approval from the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ MSC product in patients with diabetic foot ulcers.
    [Cynata Therapeutics Limited (BioSpace)]

    Press Release

    FEATURED EVENT

    EMBO: Molecular Mechanisms of Aging and Regeneration: From Hydra to Humans

    September 6 – 10, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researchers – Drug Discovery and Enzymology

    Florida State University – Tallahassee, Florida, United States

    Research Scientist – Biomolecular Response of MSCs

    CellDrop Biosciences – Laramie, Wyoming, United States

    Postdoctoral Fellow – Multiple Myeloma

    University of Arkansas for Medical Sciences – Little Rock, Arkansas, United States

    Postdoctoral Fellowships – Therapeutic Vascularization and Tissue Regeneration

    Boston Children’s Hospital – Boston, Massachusetts, United States

    Postdoctoral Research Associate – Tissue Development and Regeneration

    University of Southern California – Los Angeles, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Mesenchymal Cell News Archives Contact Us
    Mesenchymal Cell News Twitter